Literature DB >> 32042272

Normal tissue sparing using different techniques for prostate irradiation.

Barbara Melles-Bencsik1, Tamás Pócza1, Tibor Major1, Péter Ágoston1,2, Kliton Jorgo1, Csaba Polgár1,2, Csilla Pesznyák1,3.   

Abstract

AIM: The aim of this study was to investigate normal tissue sparing through dosimetric parameters of normal tissue volumes using different irradiation techniques for conventional (CFRT) and simultaneously integrated boost (SIB) schedules.
BACKGROUND: Several dose-escalation studies for localized prostate cancer (PCa) have shown advanced biochemical relapse-free (bRFS) rates and also better local control for higher total doses using either CFRT or SIB schedules. Besides the most important organs-at-risk, absorbed dose reduction of other surrounding normal tissues are also preferable. In order to analyse the normal tissue sparing, dosimetric parameters of different normal tissue volumes were examined.
MATERIALS AND METHODS: Treatment plans for 15 high risk prostate cancer patients were created using RapidArc (RA), Sliding Window (SW) IMRT and 4-field box (3D-CRT) technique. In order to evaluate normal tissue sparing, the volume of pelvic region was divided into six normal tissue cylinders with 1 cm wall thickness, located in each other.
RESULTS: All plans met the criteria of target coverage (V95%>95%). All techniques provided the same results for OARs except 3D-CRT for rectum and bilateral femoral heads. The values of V5, V10 and V15 increased in cases which included RapidArc technique and decreased for V20 and V30.
CONCLUSIONS: The dosimetric parameters for the cylindrical normal tissue volumes show that using RapidArc technique gives equal or slightly better normal tissue sparing and SIB provided the same normal tissue sparing as CFRT planned with RapidArc.
© 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Normal tissue sparing; Prostate cancer; Radiotherapy; Simultaneously integrated boost

Year:  2019        PMID: 32042272      PMCID: PMC7000957          DOI: 10.1016/j.rpor.2019.11.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  21 in total

1.  Dosimetric consequences of prostate-based couch shifts on the precision of dose delivery during simultaneous IMRT irradiation of the prostate, seminal vesicles and pelvic lymph nodes.

Authors:  Marta Adamczyk; Tomasz Piotrowski; Ewa Adamiak; Julian Malicki
Journal:  Phys Med       Date:  2013-07-13       Impact factor: 2.685

2.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate.

Authors:  A van't Riet; A C Mak; M A Moerland; L H Elders; W van der Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

3.  Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.

Authors:  Louise J Murray; Christopher M Thompson; John Lilley; Vivian Cosgrove; Kevin Franks; David Sebag-Montefiore; Ann M Henry
Journal:  Phys Med Biol       Date:  2015-01-15       Impact factor: 3.609

4.  Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

Authors:  Jeffrey V Brower; Jeffrey D Forman; Patrick A Kupelian; Daniel G Petereit; Vinai Gondi; Colleen A Lawton; Nick Anger; Sandeep Saha; Rick Chappell; Mark A Ritter
Journal:  Radiother Oncol       Date:  2016-01-02       Impact factor: 6.280

5.  Advanced optimization methods for whole pelvic and local prostate external beam therapy.

Authors:  Martin Buschmann; Yvette Seppenwoolde; Tilo Wiezorek; Kirsten Weibert; Dietmar Georg
Journal:  Phys Med       Date:  2016-04-03       Impact factor: 2.685

6.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

7.  Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.

Authors:  Eric E Yeoh; Rochelle J Botten; Julie Butters; Addolorata C Di Matteo; Richard H Holloway; Jack Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-08       Impact factor: 7.038

Review 8.  Predicting toxicity in radiotherapy for prostate cancer.

Authors:  Valeria Landoni; Claudio Fiorino; Cesare Cozzarini; Giuseppe Sanguineti; Riccardo Valdagni; Tiziana Rancati
Journal:  Phys Med       Date:  2016-04-08       Impact factor: 2.685

9.  Early toxicity of hypofractionated radiotherapy for prostate cancer.

Authors:  Pavel Krupa; Hana Ticha; Tomas Kazda; Radana Dymackova; Jana Zitterbartova; Anna Odlozilikova; Libor Kominek; Lukas Bobek; Ales Kudlacek; Pavel Slampa
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2016-03-04       Impact factor: 1.245

Review 10.  The case for hypofractionation of localized prostate cancer.

Authors:  Winnifred M Wong; Kent E Wallner
Journal:  Rev Urol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.